Webinar: Antibody Discovery Platforms and RenMab Mouse
This event has now passed. Now, you can view the Webinar on Youtube.
Biocytogen Chief Scientific Officer and Head of Drug Discovery, Benny Yang PhD. will speak on the current landscape of antibody discovery platforms, with special focus on fully human antibody mice.
Dr. Yang will explain the advantages and data-backed validation that come with using the RenMabTM Mouse for antibody discovery such as expedited screening of antibody candidates, from early discovery to in vivo efficacy investigations. Additionally, Dr. Yang will present Project Integrum for the creation of knock-out fully human antibody mice to develop novel drugs.
RenMabTM Mouse produces high-quality antibodies with affinities similar to that of wild-type and chimeric mouse antibodies, while already being fully humanized. With excitement, Dr. Yang will highlight some of Biocytogen’s progress toward global COVID-19 research efforts, including our recent isolation of antibodies that block COVID-19 spike protein from binding to human ACE2 receptors.
Benny Yang, PhD
Chief Scientific Officer & Head of Drug Discovery
Biocytogen
Dr. Yang graduated from Fudan University with a Master’s degree in Microbiology. He received his Ph.D. degree in Immunology from University of Connecticut Health Center (UCHC) and completed his postdoctoral training at New York University School of Medicine in Dr. Dan Littman’s research group. Then Dr. Yang was recruited to the Medical University of South Carolina (MUSC) as a tenure-track Assistant Professor at the Department of Microbiology and Immunology. In 2016, he joined Biocytogen and has been leading antibody drug discovery.
